CTOs on the Move

Boston Biomedical Research Institute

www.bbri.org

 
The Boston Biomedical Research Institute (BBRI) is dedicated to basic biomedical research to promote the understanding, treatment and prevention of specific human diseases. The areas of investigation concern the structure and function of muscle proteins,
  • Number of Employees: 100-250
  • Annual Revenue: $100-250 Million
  • www.bbri.org
  • 64 Grove St
    Watertown, MA USA 02472
  • Phone: 617.658.7700

Executives

Name Title Contact Details

Similar Companies

Stemline Therapeutics

Stemline Therapeutics is a clinical stage biopharmaceutical company developing oncology compounds that target cancer stem cells.

Nanosphere

Nanosphere is dedicated to enhancing medicine by providing targeted molecular diagnostic tests that can lead to earlier disease detection, optimal patient treatment and improved healthcare economics. Nanosphere’s platform, the Verigene® System, enables clinicians to rapidly identify and treat the bacteria and viruses responsible for some of the most complex, costly and deadly infectious diseases. Headquartered in Northbrook, Illinois, Nanosphere was founded in 1999 based upon technology developed at Northwestern University by Dr. Robert Letsinger and Dr. Chad Mirkin. In 2007, Nanosphere went public (NASDAQ: NSPH), and has remained committed to continued scientific discovery and innovation with more than 175 patents to its name.

Chiral Quest

Chiral Quest is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Kymanox

Kymanox is a professional services organization with a focus on project delivery. Our team of experts provide guide you and your project.

Rallybio

Rallybio is a privately-held development-stage biotechnology company incorporated in January 2018. Our ambition is to create a leading biotechnology organization that transforms the lives of patients with devastating disease, built around people with an outstanding track record in pharmaceutical research and development. We will identify and accelerate the development of highly-promising drug candidates that have strong biological rationales and that can be addressed using the well-validated therapeutic modalities of small molecules, engineered proteins, and antibodies. A part of the Technology Incubation Program at the University of Connecticut in Farmington, CT, we continue to expand our drug acquisition and development capabilities through the assembly of a team of individuals with an outstanding track record in pharmaceutical research, development, and a strong understanding of the financial components of the industry. This seasoned team enables us to search for and evaluate assets using a series of robust clinical and commercial filters that will allow us to identify and acquire a portfolio of high-quality small molecule and protein-based assets in the late discovery to early clinical stages of drug development. Named by FierceBiotech as one of its “Fierce 15” Biotech Companies of 2018, the company was recognized as being among “the most promising private biotech startups”. Rallybio has earned the support of highly-respected investors in the bioscience sector and announced in April 2018 that it had secured $37.0 million in Series A funding with lead financing from 5AM Ventures, Canaan Partners, and New Leaf Venture Partners, and additional public-sector participation from Connecticut Innovations.